← Back to Search

Anti-suicidal Effects of Buprenorphine In Depressed Individuals

Phase 3
Waitlist Available
Led By Jeffrey M Miller, MD
Research Sponsored by New York State Psychiatric Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 weeks
Awards & highlights
Pivotal Trial
All Individual Drugs Already Approved
Approved for 5 Other Conditions

Summary

This trial tests if adding low-dose buprenorphine to usual treatments can help reduce suicidal thoughts in people with major depression who haven't responded well to standard antidepressants. Buprenorphine may work by changing brain activity related to negative emotions, potentially offering faster relief from suicidal thoughts. Buprenorphine has shown potential antidepressant effects, particularly in treatment-resistant depression (TRD).

Eligible Conditions
  • Depression
  • Adolescent Suicidality
  • Suicidal Thoughts

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Changes in Beck Scale for Suicidal Ideation (SSI) scores from pre- to Week 2 post-treatment.
Secondary study objectives
Changes in functional magnetic resonance imaging (fMRI) blood oxygen- level dependent (BOLD) signal in the amygdala in response to negative vs. neutral pictures from pre- to Week 2 post-treatment

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: BuprenorphineExperimental Treatment1 Intervention
Buccal Films
Group II: PlaceboPlacebo Group1 Intervention
Buccal Films

Find a Location

Who is running the clinical trial?

New York State Psychiatric InstituteLead Sponsor
478 Previous Clinical Trials
153,973 Total Patients Enrolled
83 Trials studying Depression
10,972 Patients Enrolled for Depression
Jeffrey M Miller, MDPrincipal InvestigatorNew York State Psychiatric Institute
2 Previous Clinical Trials
50 Total Patients Enrolled
2 Trials studying Depression
50 Patients Enrolled for Depression
Mina M Rizk, MDPrincipal InvestigatorNew York State Psychiatric Institute
1 Previous Clinical Trials
~0 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top